Pemvidutide is under clinical development by Altimmune and currently in Phase II for Obesity. According to GlobalData, Phase II drugs for Obesity have a 28% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Pemvidutide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pemvidutide (ALT-801) is under development for the treatment of obesity, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease and type 2 diabetes. The drug candidate is administered subcutaneously. It is a synthetic peptide and is an analogue of oxyntomodulin. The drug candidate targets GLP-1 and glucagon receptor. It is developed based on EuPort technology.
Altimmune, is a a biopharmaceutical company. It focuses on developing liver disease and immune modulating therapies. The company’s pipeline products include ALT-801, a glucagon receptor to treat metabolic dysfunction that leads to non-alcoholic steatohepatitis (NASH). Altimmune also offers nasovax, an intranasally administered recombinant influenza vaccine; and heptcell, an immunotherapy to patients chronically infected with the hepatitis B virus; nasoshield, a vaccine for the prevention of anthrax disease following inhalation of pathogen spores. In addition, its products find its application in the treatment of acute respiratory infections, chronic viral infections, and cancer. Altimmune is headquartered in Gaithersburg, Maryland, the US.
For a complete picture of Pemvidutide’s drug-specific PTSR and LoA scores, buy the report here.